Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction

Thrombosis Research

Volumn 134, Issue 5, 2014, Pages 970-975

  Zhang, Jia Hui ^a   Tang, Xiao Fang ^a   Zhang, Yin ^a   Wang, Jing ^a   Yao, Yi ^a   Ma, Yuan Liang ^a   Xu, Bo ^a   Gao, Run Lin ^a   Gao, Zhan ^a   Chen, Jue ^a   Song, Lei ^a   Wu, Yuan ^a   Meng, Xian Min ^a   Yuan, Jin Qing ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

ABCB1; Bleeding; Clopidogrel; Polymorphisms; Thromboelastography

Indexed keywords

CLOPIDOGREL; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; ANTITHROMBOCYTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; TICLOPIDINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLEEDING; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOELASTOGRAPHY; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; GENETICS; HEMORRHAGE; MYOCARDIAL INFARCTION;

AGED; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; P-GLYCOPROTEINS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; THROMBELASTOGRAPHY; TICLOPIDINE;

EID: 84927691854     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.08.017     Document Type: Article

References (28)

1. Steg PG, James SK, Atar D, Badano L.P., Blomstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569-619.
2. Levine GN, Bates ER, Blankenship J.C., Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574-651.
3. Gurbel PA, Bliden KP, Hiatt B.L., O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908-13.
4. Tantry US, Bonello L, Aradi D., Price MJ, Jeong YH, Angiolillo DJ, et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischemia and Bleeding. J Am Coll Cardiol 2013; 62:2261-73.
5. ∗17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121:512-8.
6. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K., Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302:849-57.
7. Campo G, Fileti L, Valgimigli M., Tebaldi M, Cangiano E, Cavazza C., et al. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis 2010; 30:319-31.
8. Tang XF, Wang J, Zhang J.H., Meng XM, Xu B, Qiao SB, et al. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Eur J Clin Pharmacol 2013; 69:1103-12.
9. Gros P, Ben Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986; 323:728-31.
10. Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009; 1794: 860-71.
11. Taubert D, von Beckerath N, Grimberg G, Lazar A., Jung N, Goeser T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80:486-501.
12. Simon T, Verstuyft C, Mary-Krause M, Quteineh L., Drouet E, Meneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-75.
13. Mega JL, Close SL, Wiviott S.D., Shen L., Walker JR, Simon T, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376:1312-9.
14. Wallentin L, James S, Storey R.F., Armstrong M., Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376:1320-8.
15. Hobson AR, Petley GW, Dawkins K.D., Curzen N. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets 2007; 18:497-505.
16. Mehran R, Rao SV, Bhatt D.L., Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123:2736-47.
17. ∗2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 2011; 75:99-105.
18. Cutlip DE, Windecker S, Mehran R., Boam A, Cohen DJ, van Es GA, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation 2007; 115:2344-51.
19. Shi YY, He L. Shesis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97-8.
20. Bochsen L, Wiinberg B, Kjelgaard-Hansen M, Steinbruchel D.A., Johansson PI. Evaluation of the TEG platelet mapping assay in blood donors. Thromb J 2007; 5:3.
21. Bliden KP, DiChiara J, Tantry U.S., Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49:657-66.
22. Kwak YL, Kim JC, Choi Y.S., Yoo KJ, Song Y, Shim JK. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010; 56:1994-2002.
23. Verstuyft C, Simon T, Kim RB. Personalized medicine and antiplatelet therapy: ready for prime time? Eur Heart J 2009; 30:1943-63.
24. Liang ZY, Han YL, Zhang X.L., Li Y., Yan CH, Kang J. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention 2013; 9:316-27.
25. Zhang L, Chen Y, Jin Y., Qu F, Li J, Ma C., et al. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Thromb Res 2013; 132:81-7.
26. Wang D, Johnson AD, Papp A.C., Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C N T affects mRNA stability. Pharmacogenet Genomics 2005; 15:693-704.
27. Kimchi-Sarfaty C, Oh JM, Kim I.W., Sauna ZE, Calcagno AM, Ambudkar SV, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315:525-8.
28. Simon T, Bhatt DL, Bergougnan L, Farenc C., Pearson K, Perrin L, et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther 2011; 90:287-95.